& 2007 Wiley-Liss, Inc. Birth Defects Research (Part B) 80:253–257 (2007)

Review Article Identification of Drug-Induced Hyper- or Hypoprolactinemia in the Female Rat Based on General and Reproductive Toxicity Study Parameters

Sabine Rehm,Ã Dinesh J. Stanislaus, and Patrick J. Wier GlaxoSmithKline, King of Prussia, Pennsylvania

Observations associated with drug-induced hyper- or hypoprolactinemia in rat toxicology studies may be similar and include increased ovarian weight due to increased presence of corpora lutea. Hyperprolactinemia may be distinguished if mammary gland hyperplasia with secretion and/or vaginal mucification is observed. Reproductive toxicity study endpoints can differentiate hyper- from hypoprolactinemia based on their differential effects on estrous cycles, mating, and fertility. Although the manifestations of hyper- and hypoprolactinemia in rats generally differ from that in humans, mechanisms of drug-related changes in synthesis/release can be conserved across species and pathologically increased or decreased prolactin levels may compromise some aspect of reproductive function in all species. Birth Defects Res (Part B) 80:253–257, 2007. r 2007 Wiley-Liss, Inc.

Key words: female rats; hyperprolactinemia; hypoprolactinemia; fertility; toxicity

INTRODUCTION and cocaine, and agents that inhibit monoamine oxidases (enzymes that degrade ), such as phenelzine Prolactin is mainly synthesized in the pituitary and is and also amphetamines, are known to increase the involved in many different biologic functions including central dopaminergic tone resulting in a decrease in behavior, immunology, endocrinology, metabolism, and plasma prolactin levels (Woodman, 1997). In addition to reproduction (Woodman, 1997; Yen and Jaffe, 1999). dopamine and agents that alter dopamine content in the Genetic analysis using knockout and transgenic mice brain, other agents such as neurotransmitters can inhibit contributed significantly in understanding the role of (g-aminobutyric acid) or stimulate (serotonin, substance prolactin in target organ function (Bole-Feysot et al., P, histamine, and beta-endorphins) prolactin release from 1998; Bartke, 1999; Ormany et al., 2003; Flint et al., 2006). the pituitary (Woodman, 1997). Also neuropeptides such Effects in knockout mouse models have been grouped as as oxytocin, vasoactive intestinal peptide (VIP), thyro- the reproduction-lactation phenotype, the bone pheno- tropin-releasing hormone, and angiotensin II can stimu- type, and the behavior phenotype (Goffin et al., 1999; late prolactin release from the pituitary (Yuan and Pan, Kelly et al., 2001). 2002). Dopamine is the predominant factor inhibiting pro- In rat general toxicity studies, observations associated lactin release from the pituitary and, therefore, drug- with induced hyper- or hypo-prolactinemia can appear induced mechanisms of hyper- or hypoprolactinemia quite similar; for example, both result in increased ovary usually involve interactions with the dopaminergic weight and an increased presence (number and/or size) system (O’Conner et al., 1996; Table 1). Therefore, of corpora lutea (CL) (Gopinath et al., 1987). The dopamine antagonists, such as antipsychotic drugs following describes how hyper- vs. hypoprolactinemia sulperide or risperidone, will cause an increase in serum can be differentiated in the absence of plasma hormone prolactin, while dopamine agonists, such as amantina- data. dine and , are responsible for decreased prolactin levels (Baptista et al., 2000; Moro et al., 2001). Agents that alter the dopamine content in the tuber- oinfundibular system in the brain can also alter the *Correspondence to: Sabine Rehm,GlaxoSmithKline, 709 Swedeland Rd, plasma prolactin concentrations (Yen and Jaffe, 1999; PO Box 1539, King of Prussia PA 19406-0939. E-mail: [email protected] Vijayan and McCann, 1979; Libertun and McCann, 1976; Received 21 May 2007; Accepted 22 May 2007 Leadem and Kalra, 1985). Dopamine re-uptake inhibi- Published online in Wiley InterScience (www.interscience.wiley.com) tors, such as tricyclic antidepressants, amphetamines, DOI: 10.1002/bdrb.20126 254 REHM ET AL. Table 1 Following hypophysectomy, which significantly Examples of Drug Classes Modulating Prolactin decreases prolactin levels, the life span of CL in the non-pregnant rat is extended by 6–9 months, while Prolactin-stimulating Prolactin-inhibiting exogenous prolactin accelerates the regression of CL in these rats. Thus, increased numbers of CLs observed Dopamine receptor Dopamine receptor antagonists agonists during microscopic evaluation of the ovaries in repeat Haloperidol Bromocriptine dose toxicity studies may suggest a drug-induced a-ergocriptine impairment of prolactin secretion. Neuroleptics/antipsychotics Monoamine oxidase Dopamine antagonists, which block the inhibitory (MOA) inhibitors effect of dopamine on prolactin release, or other Remoxipride Deprenyl treatments that cause sustained prolactin increases, may Selective serotonin re-uptake 5HT receptor antagonists cause pseudopregnancy and preserve functional corpora inhibitors(SSRIs) lutea (Manson and Mattson, 1992). As a consequence, Fluoxetine Ketanserin ovarian weights are increased and hypertrophic CL can Methysergide be noted grossly and/or microscopically (Yuan and Quipazine Foley, 2002). However, prolactin can also have antig- Antihistamines Antidepressants (other) onadotrophic effects as seen during lactation, following Cimetidine Bupropion pituitary transplants, or administration of high-dose Opioids Opioid antagonist Morphine Naltrexone dopamine antagonists causing markedly increased Naloxone prolactin concentrations, decreased ovarian weights, and an extended anovulatory period (Smith, 1980; Data are from Woodman (1997); Piacentini et al. (2003); Lacau- Baptista et al., 2000; Lacruz et al., 2000; Moro et al., 2001). Mengido et al. (1996). Effects on Mammary Gland OBSERVATIONS IN RAT GENERAL TOXICITY STUDIES ASSOCIATED WITH HYPER- Prolactin is the hormone primarily responsible for OR HYPO-PROLACTINEMIA mammary gland differentiation, lobuloalveolar growth, and synthesis of all major milk components (Knight and Increased Ovarian Weight and Increased Number Peaker, 1982; Bole-Feysot et al., 1998; Brisken et al., 1999; and/or Size of Corpora Lutea Kelly et al., 2002). Therefore, depending on study In rats, prolactin has both luteotrophic and luteolytic duration and degree of hyperprolactinemia, mammary actions, depending on the stage of the estrous cycle, or if gland hyperplasia and lactogenic secretion may be cervical stimulation has occurred (as during mating), or apparent in female rats (Gopinath et al., 1987; Lucas if the rat is pregnant. (Niswender and Nett, 1988; et al., 2007). Woodman, 1997). Luteotrophic actions of prolactin, as part of the luteotrophic complex, involve maintenance of Increased Food Consumption and Body Weight CL through the induction of luteinizing hormone (LH) Gain in Female Rats receptors in luteal cells, which secrete progesterone in The role of prolactin in food consumption and body response to stimulation by LH (Bole-Feysot et al., 1998). weight gain is unclear. Dose-and time-dependent In the cycling rat, a nocturnal prolactin surge occurs increased food consumption and body weight gain may during proestrus, concomitantly with the pre-ovulatory be observed in hyperprolactinemic female, but not in LH surge, then returns to baseline levels for the male, rats (Moore et al., 1986; Heil, 1999). Likewise, a sex remainder of the estrous cycle. This prolactin surge is difference was observed for body weight gain in female thought to produce a luteolytic response in the cohort of but not in male rats treated with antipsychotic drugs CLs from prior cycles (Wuttke et al., 1971; Smith et al., sulperide or risperidone (Lacruz et al., 2000; Baptista 1975). During mating, cervical stimulation activates a et al., 2002). Mechanisms for this sex difference in rats neuroendocrine reflex of circadian nocturnal prolactin remain unclear but inhibition of leptin by increased surges, which maintain CL and its secretion of proges- prolactin levels may be one of the pathways involved terone. If a sterile mating occurs or females are artificially (Dennis et al., 2003; Sone and Osamura, 2001). Obesity is stimulated cervically during proestrus, the neuroendo- also one significant side effect of some antipsychotic crine reflex activates circadian prolactin surges that drugs, such as sulperide, that are also associated with maintain CL for approximately 12 days, after which hyperproplactinemia (Bhavnani and Levin, 1996). In- luteolysis occurs coincident with sexual receptivity and a creased body weight gain and food consumption due to return to estrous cyclicity. This phenomenon is referred hyperprolactinemia may possibly result from increased to as pseudopregnancy. metabolic activity since prolactin has been shown to As mentioned, the prolactin surge in proestrus has a affect energy metabolism by modulating ATPase activity luteolytic effect, inducing regression of non-funtional in monkey brains (Bole-Feysot et al., 1998). CL of the previous cycle. Therefore, inhibition of the proestrus prolactin surge or sustained inhibition of prolactin, as noted with ergocornine or with dopamine Vaginal Mucification and Increased Number agonists, will prevent luteolysis causing increased of Diestrus Vaginal Epithelia numbers of persisting CL (Wuttke et al., 1971; Wutke Vaginal mucification is observed with hyperprolacti- and Meites, 1971). These CL do not exceed the size nemia due to the luteotropic nature of prolactin in the of normal CL. In the non-pregnant rat, the average life- rodent. Prolactin stimulates progesterone production span of CL is 13–17 days (Malven and Sawyer, 1966). from functional CL resulting in the formation of mucin-

Birth Defects Research (Part B) 80:253–257, 2007 DOI 10.1002/bdrb HYPER- OR HYPOPROLACTINEMIA IN FEMALE RATS 255 filled tall columnar cells in the superficial layers of the pseudopregnancy) will occur if the rat is not mated and vaginal epithelium. If vaginal cytology is assessed in a if prolactin increases are sustained. One of the major fertility study, this vaginal change is evident as an functions of the proestrus prolactin surge is the induction increased number of animals in a state of persistent of luteolysis of CL from the previous cycle, and so diestrus. Similarly, treatment of rats with progestational follicular growth is unaffected by hyper- or compounds, such as progesterone receptor agonists or hypoprolactinemia. glucocorticoid receptor agonists with low selectivity against the progesterone receptor, can cause vaginal Mating mucification (Gopinath et al., 1987). Vaginal mucification can also be observed following treatments altering the Increased prolactin is associated with increased days to progesterone:estradiol ratio in favor of progesterone mating with a normal percentage showing a successful (Daly and Kramer, 1998; Yuan and Foley, 2002; Berger mating if the cohabitation period is sufficient (unpub- et al., 2005). Vaginal mucification is not expected with lished observation). The increase in the mating period is compounds that induce hypoprolactinemia. due to the fact that hyperprolactinemia produces a state of persistent diestrus for approximately 12 days followed by a brief period of sexual receptivity and ovulation Effect on Pituitary Weight or Histomorphology during which successful mating can occur. The mating Hyper- or hypoprolactinemia is usually not detected percentage will likely be reduced if the cohabitation by pituitary weight measurement or histology of routine period is less than 3 weeks. Since hypoprolactinemia hematoxilyn and eosin–stained sections. Immunohisto- does not affect normal estrous cycling, generally there is chemistry, however, may reveal increased or decreased no effect on time taken to mate or mating success. lactotroph immunoreactivity for prolactin (Spritzer et al., 1996; Oliveira et al., 1999). In estrogen-stimulated rats Fertility treated with bromocriptine, a decreased labeling index for the proliferating cell nuclear antigen and increased Once pregnancy occurs, hyperprolactinemia is not apoptotic nuclei correlated with hypoprolactinemia, associated with effects on pregnancy parameters, such indicating reduced cellular proliferation and increased as the litter size, corpora lutea number, and resorptions cell death (Yonezawa et al., 1997). (unpublished observation). Prolactin is required for the maintenance of progesterone production for up to 7 days post-mating, before placental lactogens sustain progesta- DIFFERENTIATION OF HYPER- OR tional function of the CL (Niswender and Nett, 1988). HYPOPROLACTINEMIA IN RAT Therefore, under conditions of decreased prolactin, REPRODUCTIVE TOXICITY STUDIES fertilization occurs but implantation failure can In the absence of marked hyperprolactinemia with be expected (for example with bromocriptine) due overt manifestations, such as mammary gland hyperpla- to inadequate luteal progesterone production, which sia with secretions, reproductive toxicity studies can is required to maintain the endometrium in a condition readily distinguish hyper- from hypoprolactinemia compatible with implantation (Richardson et al., 1984). (Table 2). DIFFERENTIAL MECHANISMS FOR Estrous Cycle INCREASED OVARIAN WEIGHT AND/ OR INCREASED PRESENCE OF CL Hyperprolactinemia is associated with a period of pseudopregnancy, observed as persistent diestrus, while Hyper- or hypoprolactinemia are the most common normal estrous cycles are observed with hypoprolactine- drug-related mechanisms for increased ovarian weight mia (unpublished observation). When females become associated with effects on CL. In addition to prolactin, pseudopregnant, approximately 12 days of persistent agents that inhibit the synthesis of prostaglandins can diestrus is observed followed by a brief return to also prolong the life span of the rodent CL, e.g., a sexually receptive state (Smith et al., 1975), but indomethacin (Niswender and Nett, 1988; Manson and re-initiation of pseudopregnancy (so-called repetitive Mattson, 1992). Prostaglandin F2a (PGF2a) is synthesized

Table 2 Guide for Distinguishing Hyper- or Hypo-Prolactinemia in Female Rats

Hyperprolactinemia Hypoprolactinemia

General toxicity study Ovary m Ovarian weight/CL size/number m Ovarian weight/CL number Mammary gland Secretory alveolar hyperplasia No effect Vagina Mucification No effect Body weight gain m No effect Reproductive toxicity study Estrous cycle 12 days pseudopregnancy No effect Mating m days to mate No effect Fertility No effect Implantation failure Body weight gain m No effect

Birth Defects Research (Part B) 80:253–257, 2007 DOI 10.1002/bdrb 256 REHM ET AL. by the uterus under the influence of estrogen and has hypoprolactinemia compromises lactation in both rats been identified as a luteolytic factor in rodents that and humans. blocks the action of LH, leading to decreased progester- one production. It should also be mentioned here that increased ovarian weight due to increased CL size and REFERENCES /or numbers and luteinized follicles (failure to ovulate Baptista T, Lacruz A, Acosta A, Colasante C. 2000. Naltrexone does not but proceeded luteinization) may be observed following prevent the weight gain and hyperphagia induced by the anti- pschychotic drug sulpiride in rats. Appetite 34:77–86. exposure to increased levels of gonadotrophins (Yuan Baptista T, Araujo De Baptisda E, Ying Kin NM, Beaulieu S, Walker D, and Foley, 2002). Joober R, Lalonde J, Richard D. 2002. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I.: body weight, food intake, body composition, hormones and glucose tolerance. Brain SIGNIFICANCE OF HYPER- OR Res 957:144–151. HYPOPROLACTINEMIA IN RATS Bartke A. 1999. Role of growth hormone and prolactin in the control of reproduction: what are we learning from transgenic and knock-out AND HUMANS animals? Steroids 64:598–604. Berger L, El-Alfy M, Martel C, Labrie F. 2005. Effects of dehydroepian- Prolactin and its receptor are conserved across many drosterone, Premarin and Acolbifene on histomorphology and sex species, and many of the known prolactin-releasing and - steroid receptors in the rat vagina. J Steroid Biochem Mol Biol inhibiting agents have the same influence on prolactin 96:201–215. Bhavani SM, Levin GM. 1996. Antipsychotic agents: a survey of the levels in laboratory animals and in humans. A standard prevalence, severity and burden of side effects. Int Clin Psycho- clinical definition of hyperprolactinemia is PRL consis- pharmacol 11:1–12. tently 420 ng/mL, and moderate hyperprolactinemia is Bole-Feysot C, Goffin V, Edery V, Binart N, Kelly PA. 1998. Prolactin o200 ng/mL (Vance and Thorner, 1995; Rebar, 1999). (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev Drug-related hyperprolactinemia can increase serum 19:225–268. prolactin up to about 40 ng/mL (oral contraceptives) or Brisken C, Kaur S, Chavarria TE, Binart N, Sutherland RL, Weinberg RA, 100 ng/mL (phenothiazines). Most patients with macro- Kelly PA, Ormandy CJ. 1999. Prolactin controls mammary gland adenomas have serum prolactin 4200 ng/mL, and it can development via direct and indirect mechanisms. Dev Biol 210: 96–106. exceed 5,000 ng/mL with some pituitary tumors. In Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG. 1978. humans, the sequelae of hyperprolactinemia include Prolactin-secreting tumors and hypogonadism in 22 men. New Engl (Vance and Thorner, 1995; Yen and Jaffe, 1999): J Med 299:847–852. Daly TJM, Kramer B. 1998. Alterations in rat vaginal histology by exogenous gonadotrophins. J Anat 193:469–472. 1. Galactorrhea, which occurs in 30–80% of women Dennis RG, Williams G, Vernon RG. 2003. Regulation of serum leptin and its role in the hyperphagia of lactation in the rat. J Endocrinol (Franks et al., 1977; Thorner and Besser, 1978) and 176:193–203. 14–33% of men (Thorner et al., 1977; Carter et al., 1978) Franks S, Nabarro JDN, Jacobs HS. 1977. Prevalence and presentation with hyperprolactinemia; of hyperprolactinc´mia in patients with "functionless" pituitary tumours. Lancet 309:778–780. 2. Oligomenorrhea, amenorrhea and in Freeman M. 1988. The ovarian cycle in the rat. In: Knobil E, Neill JD, women; decreased libido and/or impotence in men; editors. The physiology of reproduction. New York: Raven Press. 3. Hyperandrogenism (due to elevated adrenal andro- p 1893–1928. gens), usually with galactorrhea-amenorrhea, can be Flint DJ, Binart N, Boumard S, Kopchick JJ, Kelly P. 2006. Developmental aspects of adipose tissue in GH receptor and prolactin receptor gene seen in patients with hyperprolactinemia, although disrupted mice: site-specific effects upon proliferation, differentia- few have hirsutism; tion and hormone sensitivity. J Endocrinol 191:101–111. 4. Decreased bone density in women and men, although Goffin V, Binart N, Cle´ment-Lacroix P, Bouchard B, Bole-Feysot C, Edery the precise relationship to prolactin level is not well M, Lucas BK, Touraine P, Pezet A, Maaskant R, Pichard C, Helloco C, Baran N, Favre H, Bernichtein S, Allamando A, Oramndy C, Kelly defined; PA. 1999. Genet Anal:Biomol Engin 15:189–201. 5. Hyperinsulinemia (but normoglycemia due to Gopinath C, Prentice DE, Lewis DJ. 1987. Atlas of experimental increased insulin resistance). toxicological pathology. Norwell, MA: MTP Press Limited. p 91–103. Heil SH. 1999. Sex-specific effects of prolactin on food intake by rats. Horm Behav 35:47–54. The key interspecies difference with regard to hyper- Kelly PA, Binart N, Freemarkt M, Lucas B, Goffin V, Bouchard B. 2001. prolactinemia is that among species with periodic Prolactin receptor signal transduction pathways and actions deter- mined in prolactin receptor knockout mice. Biochem Soc 29:48–52. ovulatory cycles, only those species (rats, mice, hamsters) Kelly PA, Bachelot A, Kedzia C, Hennighausen L, Ormandy CJ, Kopchick that lack a spontaneous luteal phase experience pseudo- JJ, Binart N. 2002. The role of prolactin and growth hormone in pregnancy (Terkel, 1986). Thus while hyperprolactinemia mammary gland development. Mol Cell Endocrinol 197:127–131. Knight CH, Peaker M. 1982. Development of the mammary gland. is associated with persistent diestrus in rats, it is J Reprod Fertil 65:521–536. associated with amenorrhea in women. In both species, Lacau-Mengido IM, Libertun C, Becu-Villalobos D. 1996. Different hyperprolactinemia can interfere with hypothalamic serotonin receptor types participate in 5-hydroxytryptophan- (reduced LH pulses) and gonadal (steroid synthesis) induced and prolactin release in the female infantile rat. Neuroendocrinology 63:415–421. function. Lacruz A, Baptista T, de Mendoza S, Mendoza-Guille´n JM, Herna´ndez L. Concerning hypoprolactinemia, prolactin is required 2000. Antipsychotic drug-induced obesity in rats: correlation by rats for the maintenance of LH receptors in ovarian between leptin, insulin and body weight gain during sulpiride luteal cells, and thereby is important for progesterone treatment. Mol Psychiatry 5:70–76. Leadem CA, Kalra SP. 1985. Effects of endogenous opioid peptides and production by CL. Conversely in humans, prolactin is opiates on luteinizing hormone and prolactin secretion in ovariecto- not necessary for maintenance of LH receptors or mized rats. Neuroendocrinology 41:342–352. progesterone synthesis (Freeman, 1988; Manson and Libertun CS, McCann SM. 1976. The possible role of histamine in the Mattson, 1992). Therefore, hypoprolactinemia would control of prolactin and release. Neuroendocrinology 20:110–120. not affect conception or implantation and maintenance Lucas JN, Rudman DG, Credille KM, Irrizarry AR, Peter A, Snyder PW. of pregnancy in women as it does in rats, but 2007. The rat mammary gland: morphologic changes as an indicator

Birth Defects Research (Part B) 80:253–257, 2007 DOI 10.1002/bdrb HYPER- OR HYPOPROLACTINEMIA IN FEMALE RATS 257

of systemic hormonal perturbations induced by xenobiotics. Toxicol rat: prolactin, gonadotropin and steroid levels associated with rescue Pathol 35:199–207. of the corpus luteum of pseudopregnancy. Endocrinology 96: Malven PV, Sawyer CH. 1966. A luteolytic action of prolactin in 219–226. hypophysectomized rats. Endocrinology 79:268–274. Sone M, Osamura RY. 2001. Leptin and the pituitary. Pituitary 4:15–23. Manson JM, Mattson BA. 1992. Susceptibility of the ovary to toxic Spritzer PM, Ribeiro MF, Oliveira MC, Barbosa-Coutinho LM, Silva IS, substances. In: Mohr U, Dungworth DL, Capen CC, editors. Dahlem N, Cericatto R, Pavanato MA. 1996. Effects of tamoxifen on Pathobiology of the aging rat, Vol. 1. Washington, DC: ILSI Press. serum prolactin levels, pituitary immunoreactive prolactin cells and p 365–376. uterine growth in estradiol-treated ovariectomized rats. Horm Metab Moore BJ, Gerardo-Gettens T, Horwitz BA, Stern JS. 1986. Hyperprolacti- Res 28:171–176. nemia stimulates food intake in the female rat. Brain Res Bull 17: Terkel J. 1986. Neuroendocrinology of coitally and noncoitally induced 563–569. pseudopregnancy. Ann NY Acad Sci 464:76–94. Moro M, Inada Y, Miyata H, Komatsu H, Kojima M, Tsujii H. 2001. Effects Thorner MO, Besser GM. 1978. Bromocriptine treatment of of dopamine D2 receptor agomists in a pituitary transplantation- hyperprolactinemic hypogonadism. Acta Endocrinol 88(Suppl 216): induced hyperprolactinemia/anovulation model in rats. Clin Exp 131–146. Pharmacol Physiol 28:651–658. Thorner MO, Edwards CRW, Hanker JP, Abraham G, Besser GM. 1977. Niswender T, Nett T. 1988. Corpus luteum and its control. In: Knobil E, Prolactin and gonadotropin interaction in the male. In: Troen P, Neill JD, editors. The physiology of reproduction. New York: Raven Nankin H, editors. The testis in normal and infertile men. New York: Press. p 489–525. Raven Press. p 351–366. O’Connor JC, Cook JC, Craven SC, Van Pelt CS, Obourn JD. 1996. An in Vance ML, Thorner MO. 1995. Prolactin: hyperprolactinemic syndromes vivo battery for identifying endocrine modulators that are estrogenic and management. In: DeGroot LJ, editor. Endocrinology, 3rd ed. or dopamine regulators. Fund Appl Toxicol 33:182–195. Philadelphia: WB Saunders Co. p 394–405. Oliveira MC, Messinger HP, Tannhauser M, Barbosa-Coutinho L. 1999. Vijayan E, McCann SM. 1979. In vivo and in vitro effects of substance P Chronic effects of antidopaminergic drugs or estrogen on male and neurotensin on gonadotropin and prolactin release. Endocrinol- Wistar rat lactotrophs and somatotrophs. Braz J Med Biol Res 32: ogy 105:64–68. 1561–1564. Woodman DD. 1997. Laboratory animal endocrinology. Chichester, UK: Ormany CJ, Naylor M, Harris J, Robertson F, Horseman ND, Lindeman John Wiley & Sons. GJ, Visvader J, Kelly PA. 2003. Investigation of the transcriptional Wuttke W, Meites J. 1971. Luteolytic role of prolactin during the estrous changes underlying functional defects in the mammary gland of cycle of the rat. Proc Soc Exp Biol Med 137:988–991. prolactin receptor knockout mice. Recent Prog Hormone Res 58: Wuttke W, Cassell E, Meites J. 1971. Effects of ergocornine on serum 297–323. prolactin and LH, and on hypothalamic content of PIF and LRF. Piacentini MF, Clinckers R, Meeusen R, Sarre S, Ebinger G, Michotte Y. Endocrinology 88:37–41. 2003. Effect of bupropion on hippocampal neurotransmitters and on Yen SSC, Jaffe RB. 1999. Prolactin in human reproduction. In: Yen SSC, peripheral hormonal concentrations in the rat. J Appl Physiol 95: Jaffe RB, Barbieri RL, editors. Reproductive endocrinology, 4th ed. 652–656. Philadelphia: WB Saunders Co. p 257–283. Rebar RW. 1999. Practical evaluation of hormonal status. In: Yen SSC, Yonezawa K, Tamaki N, Kokunai T. 1997. Effects of bromocriptine and Jaffe RB, Barbieri RL, editors. Reproductive endocrinology, 4th ed. terguride on cell proliferation and apoptosis in the estrogen- Philadelphia: WB Saunders Co. p 709–747. stimulated gland of the rat. Neurol Med Chirurg Richardson BP, Turkalj I, Flu¨ ckiger E. 1984. Bromocriptine. In: Laurence 37:901–906. DR, Mclean AEM, Weatherall M, editors. Safety testing of new drugs, Yuan Y-D, Foley GL. 2002. Female reproductive system. In: Hascheck laboratory predictions and clinical performance. London: Academic WM, Rousseaux CG, Wallig MA, editor. Handbook of toxicologic Press. p 19–25. pathology, Vol. 2. San Diego, CA: Academic Press. p 847–894. Smith MS. 1980. Role of prolactin in regulating gonadotrophin secretion Yuan ZF, Pan J-T. 2002. Involvement of angiotensin II, TRH and prolactin- and gonad function in female rats. Fed Proc 39:2571–2576. releasing peptide in the estrogen-induced afternoon prolactin surge Smith MS, Freeman ME, Neill JD. 1975. The control of progesterone in female rats: studies using antisense technology. Life Sci 71: secretion during the estrous cycle and early pseudopregnancy in the 899–910.

Birth Defects Research (Part B) 80:253–257, 2007 DOI 10.1002/bdrb